StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Trading Up 0.9 %

NERV stock opened at $2.16 on Friday. The business’s fifty day moving average price is $2.32 and its 200 day moving average price is $2.74. Minerva Neurosciences has a 12-month low of $2.06 and a 12-month high of $13.49. The company has a market capitalization of $15.10 million, a PE ratio of -4.91 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.